HRP20140881T1 - Benzensulfonamidni spojevi, postupak njihove sinteze i njihova upotreba u medicini - Google Patents

Benzensulfonamidni spojevi, postupak njihove sinteze i njihova upotreba u medicini Download PDF

Info

Publication number
HRP20140881T1
HRP20140881T1 HRP20140881AT HRP20140881T HRP20140881T1 HR P20140881 T1 HRP20140881 T1 HR P20140881T1 HR P20140881A T HRP20140881A T HR P20140881AT HR P20140881 T HRP20140881 T HR P20140881T HR P20140881 T1 HRP20140881 T1 HR P20140881T1
Authority
HR
Croatia
Prior art keywords
radical
hydroxy
propionamide
substituted
benzenesulfonylamino
Prior art date
Application number
HRP20140881AT
Other languages
English (en)
Inventor
Laurence Clary
Sandrine Chambon
Laurent Chantalat
Carine Rosignoli
Olivier Roye
Jean-Claude Pascal
Marlene Schuppli
Original Assignee
Galderma Research & Development
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Research & Development filed Critical Galderma Research & Development
Publication of HRP20140881T1 publication Critical patent/HRP20140881T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/68—One oxygen atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)

Claims (15)

1. Spoj formule (I): [image] gdje: R1 predstavlja vodik, C1-10 alkil radikal, C2-10 alkenil radikal, C2-10 alkinil radikal, C1-10 alkil radikal supstituiran radikalom arila koji je nesupstituiran ili supstituiran, heteroaralkil radikal, -C(O)-R4 radikal, -SO2-R4 radikal, ili C(O)OR4 radikal, gdje R4 ima značenja data u daljnjem tekstu; R2 je atom vodika ili C1-4 alkil radikal; R3 je C1-10 alkil radikal, C2-10 alkenil radikal, C2-10 alkinil radikal, aril radikal, C1-10 alkil radikal supstituiran aril radikalom koji je nesupstituiran ili supstituiran, heterociklički radikal, C3-7 cikloalkil radikal, heteroaril radikal, ili heteroaralkil radikal; R4 je C1-10 alkil radikal, C2-10 alkenil radikal, C2-10 alkinil radikal, aril radikal, ili C1-10 alkil radikal supstituiran radikalom arila koji je nesupstituiran ili supstituiran; i n je 1; i također adicijske soli navedenog spoja formule (I) s farmaceutski prihvatljivom kiselinom, adicijske soli navedenog spoja formule (I) s farmaceutski prihvatljivom bazom, i enantiomeri navedenog spoja formule (I), gdje navedeni radikali C1-10 alkila, C2-10 alkenila, C2-10 alkinila i C3-7 cikloalkila mogu biti supstituirani jednim ili više radikala izabranih između halogena, C1-10 alkoksil i hidroksil; aril radikal je aromatski prsten na bazi ugljikovodika ili dva fuzionirana aromatična prstena na bazi ugljikovodika; heterociklički radikal je zasićen ili nezasićen, ciklički ili policiklički lanac na bazi ugljikovodika koji sadrži jedan ili više heteroatoma izabranih između O, S i N; gdje aril i heterociklički radikali mogu biti supstituirani jednom ili više grupa izabranih između C1-10 alkila, C1-10 alkoksila, arila, halogena, hidroksila, cijano, trifluorometil i nitro; heteroaril radikal je ciklički ili policiklički aromatski lanac na bazi ugljikovodika koji sadrži jedan ili više heteroatoma izabranih između O, S i N, gdje heteroaril radikal može biti supstituiran jednom ili više grupa izabranih između C1-10 alkila, C1-10 alkoksila, arila, supstituiranog arila, halogena, hidroksi, cijano, trifulorometil i nitro; heteroaralkil radikal je C1-10 alkil radikal supstituiran radikalom heteroarila, gdje heteroaralkil radikal može biti supstituiran jednom ili više grupa izabranih između C1-10 alkil, C1-10 alkoksil, halogen, hidroksil, cijano, trifluorometil i nitro; i halogen je atom fluora, klora, broma ili joda.
2. Adicijske soli spoja prema patentnom zahtjevu 1, s farmaceutski prihvatljivom kiselinom, naznačene time da je farmaceutski prihvatljiva kiselina izabrana iz grupe koja se sastoji od klorovodonične kiseline, bromovodonične kiseline, sumporne kiseline, dušične kiseline, fosforne kiseline, octene kiseline, trifluoroctene kiseline, trikloroctene kiseline, propionske kiseline, glikolne kiseline, piruvinske kiseline, jantarne kiseline, benzojeve kiseline, cinaminske kiseline, bademove kiseline, metansulfonske kiseline, paratoluensulfonske kiseline, salicilne kiseline, pikrinske kiseline, limunske kiseline, oksalne kiseline, vinske kiseline, malonske kiseline, maleinske kiseline, kamforsulfonske kiseline, i fumarne kiseline.
3. Adicijske soli spoja prema patentnom zahtjevu 1, s farmaceutski prihvatljivom bazom, naznačene time da je farmaceutski prihvatljiva baza izabrana iz grupe koja se sastoji od kalij hidroksida, natrij hidroksida, litij hidroksida, kalcij hidroksida, metilamina, entilamina, etanolamina, propilamina, izopropilamina, 4 izomera butilamina, dimetilamina, dietilamina, dietanolamina, dipropilamina, diizoproilamina, di-n-butilamina, pirolidina, piperidina, morfolina, dietanolfenilamina, trimetilamina, trietilamina, tripropilamina, kunuklidina, piridina, kinolina, izokinolina, lizina, arginina, i ornitina.
4. Spoj prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time da R3 je aril radikal, C1-10 alkil radikal supstituiran aril radikalom koji je nesupstituiran ili supstituiran, heterocikličkim radikalom, radikalom heteroarila, ili radikalom heteroaralkila; i također adicijske soli navedenog spoja s farmaceutski prihvatljivom kiselinom, adicijske soli navedenog spoja s farmaceutski prihvatljivom bazom, i enantiomeri navedenog spoja.
5. Spoj prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time da R1 predstavlja vodik, C1-10 alkil radikal, C2-10 alkenil radikal, C2-10 alkinil radikal, C1-10 alkil radikal supstituiran radikalom arila koji je nesupstituiran ili supstituiran, -C(O)-R4 radikal, ili -SO2-R4radikal, gdje R4 ima značenja data u daljnjem tekstu; R3 je aril radikal, C1-10 alkil radikal supstituiran radikalom arila koji je nesupstituiran ili supstituiran, heterociklički radikal, heteroaril radikal, ili heteroaralkil radikal; R4 je C1-10 alkil radikal, aril radikal, C1-10 alkil radikal supstituiran radikalom arila koji je nesupstituiran ili supstituiran; i također adicijske soli navedenog spoja s farmaceutski prihvatljivom kiselinom, adicijske soli navedenog spoja s farmaceutski prihvatljivom bazom, i enantiomeri navedenog spoja.
6. Spoj prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time da R1 predstavlja C1-10 alkil radikal, C1-10 alkil radikal supstituiran radikalom arila koji je nesupstituiran ili supstituiran, -C(O)-R4 radikal, ili -SO2-R4 radikal, gdje R4 ima značenja data u daljnjem tekstu; R2 je atom vodika; R3 je aril radikal, C1-10 alkil radikal supstituiran radikalom arila koji je nesupstituiran ili supstituiran, heterociklički radikal, heteroaril radikal, ili heteroaralkil radikal; R4 je C1-10 alkil radikal, aril radikal, C1-10 radikal alkila supstituiran radikalom arila koji je nesupstituiran ili supstituiran; i također adicijske soli navedenog spoja s farmaceutski prihvatljivom kiselinom, adicijske soli navedenog spoja s farmaceutski prihvatljivom bazom, i enantiomeri navedenog spoja.
7. Spoj prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time da R1 predstavlja C1-10 alkil radikal, C1-10 alkil radikal supstituiran radikalom arila koji je nesupstituiran ili supstituiran, -C(O)-R4 radikal, ili -SO2-R4 radikal, gdje R4 ima značenja data u daljnjem tekstu; R2 je atom vodika; R3 je heterociklički radikal, heteroaril radikal, ili heteroaralikl radikal; R4 je C1-10 alkil radikal, aril radikal, ili C1-10 alkil radikal supstituiran radikalom arila koji je nesupstituiran ili supstituiran; i također adicijske soli navedenog spoja s farmaceutski prihvatljivom kiselinom, adicijske soli navedenog spoja s farmaceutski prihvatljivom bazom, i enantiomeri navedenog spoja.
8. Spoj prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time da R1 predstavlja C1-10 alkil radikal, C1-10 alkil radikal supstituiran radikalom arila koji je nesupstituiran ili supstituiran, -C(O)-R4 radikal, ili -SO2-R4 radikal, gdje R4 ima značenja data u daljnjem tekstu; R2 je atom vodika; R3 je heteroaril radikal; R4 je C1-10 alkil radikal, aril radikal, C1-10 alkil radikal supstituiran radikalom arila koji je nesupstituiran ili supstituiran; i također adicijske soli navedenog spoja s farmaceutski prihvatljivom kiselinom, adicijske soli navedenog spoja s farmaceutski prihvatljivom bazom, i enantiomeri navedenog spoja.
9. Spoj prema bilo kojem od patentnih zahtjeva 1 do 8, naznačen time da je spoj izabran iz grupe koja se sastoji od: 1) 3-[(4-but-2-iniloksibenzensulfonil)metilamino]-N-hidroksi-2-(4-metansulfonilpiperazin-1-il)propionamid; 2) (S)-3-(4-but-2-iniloksibenzensulfonilamino)-N-hiroksi-2-(4-metansulfonilpiperazin-1-il)propionamid; 3) (S)-3-(4-benziloksibenzensulfonilamino)-N-hidroksi-2-(4-metansulfonilpiperazin-1-il)propionamid; 4) (S)-3-[(4-benziloksibenzensulfonil)metilamino]-N-hidroksi-2-(4-metansulfonilpiperazin-1-il)propionamid; 5) (S)-N-hidroksi-2-(4-metansulfonilpiperazin-1-il)-3-[4-(2-metilkinolin-4-ilmetoksi)benzensulfonilamino]propionamid; 6) (S)-N-hidroksi-2-(4-metansulfonilpiperazin-1-il)-3-[4-(naftalen-1-ilmetoksi)benzensulfonilamino]propionamid; 7) (S)-N-hidroksi-2-(4-metansulfonilpiperazin-1-il)-3-(4-propoksibenzensulfonilamino)propionamid; 8) (S)-3-[4-(3-cijanobenziloksi)benzensulfonilamino]-N-hidroksi-2-(4-metansulfonilpiperazin-1-il)propionamid; 9) (S)-3-[4-(4-cijanobenziloksi)benzensulfonilamino]-N-hidroksi-2-(4-metansulfonilpiperazin-1-il)propionamid; 10) benzil 4-{(S)-1-hidroksikarbamoil-2-[4-(2-metilkinolin-4-ilmetoksi)benzensulfonilamino]etil}piperazin-1-karboksilat; 11) (S)-N-hidroksi-2-(4-metansulfonilpiperazin-1-il)-3-[4-(2-fenilpiridin-4-ilmetoksi)benzensulfonilamino]propionamid; 12) (R)-N-hidroksi-2-(4-metansulfonilpiperazin-1-il)-3-[4-(2-metilkinolin-4-ilmetoksi)benzensulfonilamino]propionamid; 13) (S)-N-hidroksi-3-[4-(2-metilkinolin-4-ilmetoksi)benzensulfonilamino]-2-piperazin-1-il-propionamid; 14) (S)-N-hidroksi-2-(4-metansulfonilpiperazin-1-il)-3-[4-(2-metilkinolin-4-ilmetoksi)benzensulfonilamino]propionamid hidroklorid; 15) terc-butil 3-{4-[(S)-2-hidroksikarbamoil-2-(4-metansulfonilpiperazin-1-il)etilsulfamoil]fenoksimetil}-2-metilindol-1-karboksilat di(trifluoroacetat); 16) (S)-N-hidroksi-2-(4-metansulfonilpiperazin-1-il)-3-[4-(kinolin-4-ilmetoksi)benzensulfonilamino]propionamid; 17) (S)-2-(4-benzilpiperazin-1-il)-N-hidroksi-3-[4-(2-metilkinolin-4-ilmetoksi)benzensulfonilamino]propionamid; 18) (S)-2-[4-(4-fluorobenzil)piperazin-1-il]-N-hidroksi-3-[4-(2-metilkinolin-4-ilmetoksi)benzensulfonilamino]propionamid; 19) (S)-2-(4-etilpiperazin-1-il)-N-hidroksi-3-[4-(2-metilkinolin-4-ilmetoksi)benzensulfonilamino]propionamid; 20) (S)-N-hidroksi-3-[4-(2-metilkinolin-4-ilmetoksi)benzensulfonilamino]-2-[4-(4-trifluorometil-benzil)piperazin-1-il]propionamid; 21) (S)-N-hidroksi-2-[4-(4-metilbenzil)piperazin-1-il]-3-[4-(2-metilkinolin-4-ilmetoksi)benzensulfonilamino]propionamid; 22) (S)-3-[4-(benzoizoksazol-3-ilmetoksi)benzensulfonilamino]-N-hidroksi-2-(4-metansulfonilpiperazin-1-il)propionamid; 23) (S)-N-hidroksi-2-(4-izobutirilpiperazin-1-il)-3-[4-(2-metilkinolin-4-ilmetoksi)benzensulfonilamino]propionamid; 24) (S)-N-hidroksi-2-[4-(2-metilpropan-1-sulfonil)piperazin-1-il]-3-[4-(2-metilkinolin-4-ilmetoksi)benzensulfonilamino]propionamid; 25) (S)-N-hidroksi-2-(4-metanesulfonilpiperazin-1-il)-3-[4-(2-trifluorometilpirazolo[1,5-a]piridin-3-ilmetoksi)benzensulfonilamino]propionamid; 26) (S)-N-hidroksi-3-[4-(2-metilkinolin-4-ilmetoksi)benzensulfonilamino]-2-[4-(propan-2-sulfonil)piperazin-1-il]propionamid; 27) (S)-2-(4-benzilpiperazin-1-il)-N-hidroksi-3-[4-(2-trifluorometilpirazolo[1,5-a]piridin-3-ilmetoksi)benzensulfonilamino]propionamid; 28) (S)-2-(4-acetilpiperazin-1-il)-N-hidroksi-3-[4-(2-metilkinolin-4-ilmetoksi)benzensulfonilamino]propionamid; 29) (S)-N-hidroksi-2-(4-metansulfonilpiperazin-1-il)-3-{propil-[4-(kinolin-4-ilmetoksi)benzensulfonil]amino}propionamid; 30) (S)-2-(4-benzensulfonilpiperazin-1-il)-N-hidroksi-3-[4-(pirazolo[1,5-a]piridin-3-ilmetoksi)benzensulfonilamino]propionamid; 31) (S)-2-(4-benzilpiperazin-1-il)-N-hidroksi-3-[4-(1-metilpiperidin-4-ilmetoksi)benzensulfonilamino]propionamid; 32) (S)-2-[4-(4-fluorobenzoil)piperazin-1-il]-N-hidroksi-3-[4-(3-m-tolil-propoksi)benzensulfonilamino]propionamid; 33) (S)-N-hidroksi-3-[4-(2-metilnaftalen-1-ilmetoksi)benzensulfonilamino]-2-(4-propionilpiperazin-1-il)propionamid; 34) (S)-N-hidroksi-3-[4-(4-metilpentiloksi)benzensulfonilamino]-2-(4-fenilacetilpiperazin-1-il)propionamid; 35) (S)-N-hidroksi-2-(4-metansulfonilpiperazin-1-il)-3-[4-(2-metilpiridin-4-ilmetoksi)benzensulfonilamino]propionamid; 36) (S)-N-hidroksi-3-[4-(2-metilbenzofuran-3-ilmetoksi)benzensulfonilamino]-2-[4-(propan-2-sulfonil)piperazin-1-il]propionamid; i 37) (S)-2-(4-benzilpiperazin-1-il)-N-hidroksi-3-[4-(2-izopropil-1H-indol-3-ilmetoksi)benzensulfonilamino]propionamid.
10. Spoj, adicijske soli navedenog spoja s farmaceutski prihvatljivom kiselinom, adicijske soli navedenog spoja s farmaceutski prihvatljivom bazom, ili enantiomeri navedenog spoja prema bilo kojem od patentnih zahtjeva 1 do 9, kao lijek.
11. Spoj prema bilo kojem od patentnih zahtjeva 1 do 9, za upotrebu u liječenju inflamatornih bolesti ili poremećaja koji uključuju proizvodnju TNF-α, pri čemu su bolest ili poremećaj izabrani iz grupe koja se sastoji od septičkog šoka, kemodinamičkog šoka, malarije, inflamatorne bolesti crijeva (IBD) kao što je Kronova bolest i ulcerativni kolitis, inflamatorna bolest kostiju, mikobakterijske infekcije, meningitis, fibrotične bolesti, bolesti srca, ishemijski napad, odbacivanje transplantata, rak, ateroskleroza, pretilost, bolesti koje obuhvaćaju fenomene angiogeneze, autoimune bolesti, osteoartritis, reumatoidni artritis, ankilozirajući spondilitis, kronični juvenilni artritis, multipla skleroza, HIV, od insulina nezavisni dijabetes (IND), alergijske bolesti, astma, kronična opstruktivna bolest pluća (COPD) i upale oka.
12. Spoj prema bilo kojem od patentnih zahtjeva 1 do 9, za upotrebu u liječenju inflamatornih bolesti kože, psorijaze, atopičnog dermatitisa i / ili psorijatičnog artritisa.
13. Spoj prema bilo kojem od patentnih zahtjeva 1 do 9, za upotrebu u liječenju neuroloških patoloških stanja inflamatorne prirode koji uključuju proizvodnju TNF-α, izabrano iz grupe koja se sastoji od Alzheimerove bolesti, Parkinsonove bolesti, parkinsonizama, amiotrofične lateralne skleroze, autoimunih bolesti živčanog sustava, autonomne bolesti živčanog sustava, bola u leđima, cerebralnog edema, cerebrovaskularnih poremećaja, demencije, autoimune bolesti koja demijelinizira vlakna živčanog sustava , dijabetske neuropatije, encefalitisa, encefalomijelitisa, epilepsije, sindroma kroničnog umora, gigantocelularnog arteritisa, Guillain-Barré-ovog sindroma, glavobolje, multipla skleroze, neuralgije, bolesti perifernog živčanog sustava, polineuropatije, poliradikuloneuropatije, radikulopatije, paralize respiratornih organa, bolesti kičmene moždine, Tourette-ovog sindroma, vaskulitisa centralnog živčanog sustava, Huntington-ove bolesti i moždanog udara.
14. Farmaceutski pripravak, naznačen time da sadrži u nosaču koji je farmaceutski prihvatljiv i kompatibilan s režimom administriranja izabranim za ovaj pripravak, najmanje jedan spoj prema bilo kojem od patentnih zahtjeva 1 do 9, koji također može biti u jednom od svojih enantiomernih oblika ili u obliku jedne od njegovih farmaceutski prihvatljivih soli.
15. Spoj prema patentnom zahtjevu 1, naznačen time da je spoj: (S)-N-hidroksi-3-[4-(2-metilkinolin-4-ilmetoksi)benzensulfonilamino]-2-[4-(propan-2-sulfonil)piperazin-1-il]propionamid.
HRP20140881AT 2009-06-30 2014-09-16 Benzensulfonamidni spojevi, postupak njihove sinteze i njihova upotreba u medicini HRP20140881T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0954460A FR2947268B1 (fr) 2009-06-30 2009-06-30 Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
PCT/FR2010/051331 WO2011001089A1 (fr) 2009-06-30 2010-06-28 Nouveaux composés benzène-sulfonamides, leur procédé de synthèse et leur utilisation en médecine ainsi qu'en cosmétique

Publications (1)

Publication Number Publication Date
HRP20140881T1 true HRP20140881T1 (hr) 2014-12-19

Family

ID=41600633

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20140881AT HRP20140881T1 (hr) 2009-06-30 2014-09-16 Benzensulfonamidni spojevi, postupak njihove sinteze i njihova upotreba u medicini

Country Status (21)

Country Link
US (5) US8420632B2 (hr)
EP (2) EP2801568A1 (hr)
JP (2) JP5607154B2 (hr)
KR (2) KR20140095108A (hr)
CN (1) CN102471260B (hr)
AU (1) AU2010267872C1 (hr)
CA (1) CA2764193C (hr)
CY (1) CY1115734T1 (hr)
DK (1) DK2448920T3 (hr)
ES (1) ES2501640T3 (hr)
FR (1) FR2947268B1 (hr)
HK (1) HK1206006A1 (hr)
HR (1) HRP20140881T1 (hr)
IN (1) IN2011KN05169A (hr)
MX (1) MX2011013130A (hr)
PL (1) PL2448920T3 (hr)
PT (1) PT2448920E (hr)
RU (2) RU2528826C2 (hr)
SI (1) SI2448920T1 (hr)
SM (1) SMT201400168B (hr)
WO (1) WO2011001089A1 (hr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2947268B1 (fr) 2009-06-30 2011-08-26 Galderma Res & Dev Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
FR2950057B1 (fr) * 2009-09-17 2011-08-26 Galderma Res & Dev Nouveaux composes benzene-carboxylamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
US9586832B2 (en) * 2013-03-15 2017-03-07 Dru L. DeLaet Method for destruction of halons
US20140275108A1 (en) * 2013-03-15 2014-09-18 Galderma Research & Development Novel benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics
CN103224476A (zh) * 2013-05-25 2013-07-31 上高县瑞雅精细化工有限公司 二乙醇胺法制备1-[2-(2-羟基乙氧基)乙基]哌嗪新工艺
FR3030521B1 (fr) * 2014-12-23 2019-07-26 Galderma Research & Development Nouveaux composes heterocycliques et leur utilisation en medecine ainsi qu'en cosmetique
EP3199534B1 (en) 2016-02-01 2018-09-05 Galderma Research & Development Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine and cosmetics

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506242A (en) 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
DK0861236T4 (da) 1995-11-13 2006-12-18 Sanofi Aventis Deutschland Cykliske og heterocykliske N-substituerede alphaiminohydroxam- og carboxylsyrer
TW453995B (en) 1995-12-15 2001-09-11 Novartis Ag Certain alpha-substituted arylsulfonamido acetohydroxamic acids
TW448172B (en) * 1996-03-08 2001-08-01 Pharmacia & Upjohn Co Llc Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation
BR9712525A (pt) 1996-10-16 1999-10-19 American Cyanamid Co O preparo e uso de ácidos orto-sulfonamido aril hidrox‰micos como inibidores da metaloproteinase matricial e da tace
ATE229949T1 (de) 1996-10-16 2003-01-15 American Cyanamid Co Herstellung und verwendung von ortho-sulfonamido- heteroarylhydroxamsäuren als matrix- metalloproteinase und tace inhibitoren
KR20000049198A (ko) 1996-10-16 2000-07-25 윌리암 에이취 캘넌, 에곤 이 버그 매트릭스 메탈로프로티나아제 및 ｔａｃｅ 억제제로서의 베타-설폰아미도 하이드록스암산
AU743901B2 (en) 1996-10-16 2002-02-07 Wyeth Holdings Corporation Ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloprote inase and tace inhibitors
JP3563411B2 (ja) 1997-01-23 2004-09-08 エフ・ホフマン−ラ ロシュ アーゲー スルファミド−メタロプロテアーゼ阻害剤
KR20010041089A (ko) 1998-02-19 2001-05-15 윌리암 에이취 캘넌, 에곤 이 버그 매트릭스 메탈로프로테이나제 억제제로서의ｎ-하이드록시-2-(알킬, 아릴, 또는 헤테로아릴 설파닐,설피닐 또는 설포닐)-3-치환된 알킬, 아릴 또는헤테로아릴아미드
JP3092798B2 (ja) * 1998-06-30 2000-09-25 日本電気株式会社 適応送受信装置
CZ20012294A3 (cs) * 1998-12-22 2001-12-12 F. Hoffmann-La Roche Ag Sulfonamidové hydroxamáty
AR035313A1 (es) 1999-01-27 2004-05-12 Wyeth Corp Inhibidores de tace acetilenicos de acido hidroxamico de sulfonamida a base de alfa-aminoacidos, composiciones farmaceuticas y el uso de los mismos para la manufactura de medicamentos.
AR035478A1 (es) 1999-01-27 2004-06-02 Wyeth Corp Acido amida-hidroxamico, acido acetilenico, beta-sulfonamido y fosfinico como inhibidores de la tace, uso de los mismos para la manufactura de un medicamento y composicion farmaceutica que los contiene
US6326516B1 (en) * 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
ATE420068T1 (de) * 2001-09-07 2009-01-15 Kaken Pharma Co Ltd Reverse hydroxamsäurederivate
EP1440057A1 (en) * 2001-11-01 2004-07-28 Wyeth Holdings Corporation Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors
TW200616612A (en) * 2004-10-08 2006-06-01 Wyeth Corp Method for the teatment of polycystic kidney disease field of invention
US20080085893A1 (en) 2006-10-06 2008-04-10 Shyh-Ming Yang Matrix metalloprotease inhibitors
FR2947268B1 (fr) * 2009-06-30 2011-08-26 Galderma Res & Dev Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique

Also Published As

Publication number Publication date
US8420632B2 (en) 2013-04-16
CA2764193A1 (en) 2011-01-06
PL2448920T3 (pl) 2015-08-31
US20150158834A1 (en) 2015-06-11
RU2528826C2 (ru) 2014-09-20
CA2764193C (en) 2016-01-19
MX2011013130A (es) 2012-02-13
RU2014127843A (ru) 2016-01-27
EP2448920B1 (fr) 2014-08-13
JP2014224152A (ja) 2014-12-04
SMT201400168B (it) 2015-01-15
US8633196B2 (en) 2014-01-21
US20130172363A1 (en) 2013-07-04
US9365529B2 (en) 2016-06-14
KR20120044350A (ko) 2012-05-07
IN2011KN05169A (hr) 2015-07-17
KR20140095108A (ko) 2014-07-31
PT2448920E (pt) 2014-09-17
US20120323006A1 (en) 2012-12-20
CN102471260A (zh) 2012-05-23
DK2448920T3 (da) 2014-09-29
FR2947268A1 (fr) 2010-12-31
CY1115734T1 (el) 2017-01-25
US20140107129A1 (en) 2014-04-17
AU2010267872C1 (en) 2014-04-10
HK1206006A1 (en) 2015-12-31
CN102471260B (zh) 2014-10-22
AU2010267872B2 (en) 2013-10-10
ES2501640T3 (es) 2014-10-02
SI2448920T1 (sl) 2014-12-31
US20160280650A1 (en) 2016-09-29
FR2947268B1 (fr) 2011-08-26
JP2012531460A (ja) 2012-12-10
JP5607154B2 (ja) 2014-10-15
WO2011001089A1 (fr) 2011-01-06
US8980897B2 (en) 2015-03-17
KR101513783B1 (ko) 2015-04-20
EP2801568A1 (fr) 2014-11-12
EP2448920A1 (fr) 2012-05-09
AU2010267872A1 (en) 2012-01-19
RU2012102925A (ru) 2013-08-10

Similar Documents

Publication Publication Date Title
HRP20140881T1 (hr) Benzensulfonamidni spojevi, postupak njihove sinteze i njihova upotreba u medicini
HRP20211002T1 (hr) 1,3-tiazol-2-il supstituirani benzamidi
JP2012523440A5 (hr)
JP2012531460A5 (hr)
JP2012515724A5 (hr)
HRP20211282T1 (hr) Oksisteroli i postupci njihovog korištenja
HRP20191755T1 (hr) Alkoksipirazoli kao aktivatori topljive gvanilat ciklaze
NL1028599C2 (nl) Verbindingen voor de behandeling van ziekten.
JP2013010793A5 (hr)
CA2758474A1 (en) Novel p2x7r antagonists and their use
TWI687396B (zh) N-[4-(1-胺基乙基)苯基]磺醯胺衍生物掌性解析之方法
JP6592510B2 (ja) Ｐ２ｘ７調節因子
AU2018216954B2 (en) Piperazine derivatives for influenza virus inhibition
JP2008519794A5 (hr)
JP2015512951A5 (hr)
WO2010115836A4 (en) Substituted piperidines as ccr3 antagonists
JP2013010792A5 (hr)
MX2007001341A (es) Carboxamidas de indolizina y sus derivados aza y diaza.
EA201370184A1 (ru) Гетероарильные производные
HRP20170695T1 (hr) Fenil-3-aza-biciklo[3.1.0]heks-3-il-metanoni i njihova uporaba u obliku lijeka
JP2008521775A5 (hr)
HRP20201379T1 (hr) Antibakterijski spojevi koji imaju široki spektar djelovanja
JP6452731B2 (ja) アミノカルボニルカルバメート化合物
HRP20180973T1 (hr) Supstituirani tiazolski ili oksazolski antagonisti p2x7 receptora
HRP20230798T1 (hr) Inhibitori transglutaminaze 2 (tg2)